(VRTX) Vertex Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 109.091m USD | Total Return: 0.6% in 12m
Cystic Fibrosis Drugs, Gene Therapies, Pain Management
Total Rating 51
Safety 78
Buy Signal -0.57
Biotechnology
Industry Rotation: -4.2
Industry Rotation: -4.2
Market Cap:
109B
Avg Turnover: 476M
Avg Turnover: 476M
Risk 3d forecast
Volatility28.1%
VaR 5th Pctl4.70%
VaR vs Median1.36%
Reward TTM
Sharpe Ratio0.07
Rel. Str. IBD29.9
Rel. Str. Peer Group22.8
Character TTM
Beta0.461
Beta Downside0.550
Hurst Exponent0.283
Drawdowns 3y
Max DD29.07%
CAGR/Max DD0.30
CAGR/Mean DD0.98
EPS (Earnings per Share)
EPS CAGR: 5.94%
EPS Trend: 3.5%
EPS Trend: 3.5%
Last SUE: 0.03
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 8.55%
Rev. Trend: 97.2%
Rev. Trend: 97.2%
Last SUE: -0.15
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: VRTX Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader focused on developing transformative small molecule and genetic therapies for serious diseases. The company maintains a dominant market position in the treatment of cystic fibrosis (CF) through its portfolio of CFTR modulators, including TRIKAFTA/KAFTRIO and KALYDECO. Beyond CF, Vertex has expanded its commercial and clinical reach into sickle cell disease, beta thalassemia, acute pain, and Type 1 Diabetes.
The company operates within the biotechnology sector, where value is primarily driven by high-margin intellectual property and the successful navigation of multi-phase clinical trials. Vertex utilizes a specialty pharmacy distribution model, selling its high-value therapeutics directly to specialized distributors, hospitals, and clinics rather than through general retail channels.
Investors should consult ValueRay to analyze the underlying valuation metrics and risk factors associated with this clinical pipeline. Founded in 1989 and headquartered in Boston, Vertex continues to diversify its revenue streams through advancements in mRNA therapeutics and small molecule correctors for kidney and muscular diseases.
- Dominant cystic fibrosis franchise generates consistent high-margin revenue and cash flow
- CASGEVY commercial launch drives diversification into sickle cell and thalassemia markets
- Suzetrigine regulatory approval milestones expand portfolio into non-opioid acute pain management
- Clinical pipeline progression in kidney disease and diabetes mitigates concentration risk
- Global reimbursement negotiations and patent longevity influence long-term valuation stability
Piotroski VR‑10 (Strict)
6.5
| Net Income: 4.34b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 19.51 > 1.0 |
| NWC/Revenue: 64.05% < 20% (prev 56.09%; Δ 7.96% < -1%) |
| CFO/TA 0.16 > 3% & CFO 4.24b > Net Income 4.34b |
| Net Debt (-5.26b) to EBITDA (5.19b): -1.01 < 3 |
| Current Ratio: 3.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (256.3m) vs 12m ago -1.23% < -2% |
| Gross Margin: 86.28% > 18% (prev 0.86%; Δ 8.54k% > 0.5%) |
| Asset Turnover: 49.65% > 50% (prev 48.51%; Δ 1.14% > 0%) |
| Interest Coverage Ratio: 377.6 > 6 (EBITDA TTM 5.19b / Interest Expense TTM 10.3m) |
Altman Z''
6.95
| A: 0.30 (Total Current Assets 11.73b - Total Current Liabilities 3.88b) / Total Assets 26.48b |
| B: 0.55 (Retained Earnings 14.59b / Total Assets 26.48b) |
| C: 0.16 (EBIT TTM 3.89b / Avg Total Assets 24.68b) |
| D: 2.05 (Book Value of Equity 14.62b / Total Liabilities 7.12b) |
| Altman-Z'' Score: 6.95 = AAA |
Beneish M
-2.88
| DSRI: 1.00 (Receivables 2.00b/1.81b, Revenue 12.26b/11.10b) |
| GMI: 1.00 (GM 86.28% / 86.03%) |
| AQI: 1.11 (AQ_t 0.50 / AQ_t-1 0.45) |
| SGI: 1.10 (Revenue 12.26b / 11.10b) |
| TATA: 0.00 (NI 4.34b - CFO 4.24b) / TA 26.48b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of VRTX shares?
As of May 17, 2026, the stock is trading at USD 436.95 with a total of 1,287,961 shares traded.
Over the past week, the price has changed by +1.66%, over one month by -1.08%, over three months by -8.46% and over the past year by +0.59%.
Over the past week, the price has changed by +1.66%, over one month by -1.08%, over three months by -8.46% and over the past year by +0.59%.
Is VRTX a buy, sell or hold?
Vertex Pharmaceuticals has received a consensus analysts rating of 3.85.
Therefore, it is recommended to buy VRTX.
- StrongBuy: 14
- Buy: 4
- Hold: 14
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the VRTX price?
| Analysts Target Price | 549.5 | 25.8% |
Vertex Pharmaceuticals (VRTX) - Fundamental Data Overview
as of 12 May 2026
P/E Trailing = 25.5086 P/E Forward = 22.6244
P/S = 8.9287
P/B = 5.6343
P/EG = 1.615
Revenue TTM = 12.26b USD
EBIT TTM = 3.89b USD
EBITDA TTM = 5.19b USD
Long Term Debt = 1.99b USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 82.8m USD (from shortTermDebt, last fiscal year)
Debt = 1.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.26b USD (recalculated: Debt 1.99b - CCE 7.25b)
Enterprise Value = 103.83b USD (109.09b + Debt 1.99b - CCE 7.25b)
Interest Coverage Ratio = 377.6 (Ebit TTM 3.89b / Interest Expense TTM 10.3m)
EV/FCF = 27.98x (Enterprise Value 103.83b / FCF TTM 3.71b)
FCF Yield = 3.57% (FCF TTM 3.71b / Enterprise Value 103.83b)
FCF Margin = 30.28% (FCF TTM 3.71b / Revenue TTM 12.26b)
Net Margin = 35.40% (Net Income TTM 4.34b / Revenue TTM 12.26b)
Gross Margin = 86.28% ((Revenue TTM 12.26b - Cost of Revenue TTM 1.68b) / Revenue TTM)
Gross Margin QoQ = 86.85% (prev 85.56%)
Tobins Q-Ratio = 3.92 (Enterprise Value 103.83b / Total Assets 26.48b)
Interest Expense / Debt = 0.17% (Interest Expense 3.30m / Debt 1.99b)
Taxrate = 17.68% (221.5m / 1.25b)
NOPAT = 3.20b (EBIT 3.89b * (1 - 17.68%))
Current Ratio = 3.02 (Total Current Assets 11.73b / Total Current Liabilities 3.88b)
Debt / Equity = 0.10 (Debt 1.99b / totalStockholderEquity, last quarter 19.36b)
Debt / EBITDA = -1.01 (Net Debt -5.26b / EBITDA 5.19b)
Debt / FCF = -1.42 (Net Debt -5.26b / FCF TTM 3.71b)
Total Stockholder Equity = 18.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.58% (Net Income 4.34b / Total Assets 26.48b)
RoE = 23.93% (Net Income TTM 4.34b / Total Stockholder Equity 18.13b)
RoCE = 19.33% (EBIT 3.89b / Capital Employed (Equity 18.13b + L.T.Debt 1.99b))
RoIC = 17.66% (NOPAT 3.20b / Invested Capital 18.13b)
WACC = 7.47% (E(109.09b)/V(111.08b) * Re(7.60%) + D(1.99b)/V(111.08b) * Rd(0.17%) * (1-Tc(0.18)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -68.89 | Cagr: -0.79%
[DCF] Terminal Value 73.22% ; FCFF base≈3.71b ; Y1≈2.44b ; Y5≈1.11b
[DCF] Fair Price = 117.2 (EV 24.48b - Net Debt -5.26b = Equity 29.74b / Shares 253.8m; r=7.47% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 3.55 | EPS CAGR: 5.94% | SUE: 0.03 | # QB: 0
Revenue Correlation: 97.21 | Revenue CAGR: 8.55% | SUE: -0.15 | # QB: 0
EPS current Quarter (2026-06-30): EPS=4.74 | Chg30d=+0.36% | Revisions=+9% | Analysts=22
EPS next Quarter (2026-09-30): EPS=4.96 | Chg30d=-0.18% | Revisions=+38% | Analysts=22
EPS current Year (2026-12-31): EPS=19.17 | Chg30d=+0.08% | Revisions=-16% | GrowthEPS=+4.2% | GrowthRev=+8.6%
EPS next Year (2027-12-31): EPS=21.59 | Chg30d=-1.39% | Revisions=-50% | GrowthEPS=+12.6% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: -50%